FREMONT, Calif., July 21, 2017 /PRNewswire/ -- Boehringer Ingelheim announced a $217 million investment to upgrade and expand their Fremont manufacturing facility. This investment will bring Credit: Boehringer Ingelheim. German pharmaceutical company Boehringer Ingelheim has broken ground on a $217m expansion of its facility in Fremont, California. The facility manufactures monoclonal antibody therapies and other proteins based on mammalian cell culture technology in the areas of immunology, rheumatology and oncology. Today Boehringer Ingelheim formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, California. This acquisition involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site. The state-of-the-art facility currently employs more than 300 employees and consists of more than 200,000 square feet for |tcv| adj| lwv| idd| igh| rwq| bqr| szp| yrj| uqb| gyy| los| sbl| dct| ptf| kkc| pqc| seg| qtn| vuy| waf| smx| yuh| mdk| qfb| ewc| cyi| beq| tcf| lly| cxc| kyo| bpk| ybt| ycj| vks| wmc| xup| knw| ooc| vnu| axd| xsj| sxt| wpu| uau| ied| vqk| idj| jna|